

Please type a plus sign inside this box

OCT 03 2006

P/D/SB/08A(05/03)

Approved for use through 05/31/2003, OMB 0651-0031

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet	1	of	2	Application Number	10/520,014
				Filing Date	March 6, 2006
				First Named Inventor	Ansorge et al.
				Art Unit	
				Examiner Name	
				Attorney Docket Number	013183.00044

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
CB	1	DE 101 00 052 A 1	07-11-2002	Institut für Medizintechnologie Magdeburg GmbH		
CB	2	WO 91/08760	06-27-1991	Brigham and Women's Hospital		
CB	3	WO 95/04533	02-16-1995	Andrulis Pharmaceuticals Corporation		
CB	4	WO 96/12737	05-02-1996	Immologic Pharmaceutical Corporation		
CB	5	WO 01/54707 A2	08-02-2001	Meltec Multi- Epitope-Ligand- Technologies GmbH		
CB	6	WO 01/89569 A1	11-29-2001	Institut für Medizintechnologie Magdeburg GmbH IMTM		

Examiner  
Signature

/Christina Bradley/ (11/17/2006)

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign inside this box +

PTO/SB/08B(05/03)

Approved for use through 05/31/2003, OMB 0651-0031

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	10/520,014
				Filing Date	March 6, 2006
				First Named Inventor	Ansorge, et al.
				Group Art Unit	
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	013183.00044

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
CB	1	ANSORGE, et al.; Dipeptidyl Peptidase IV/CD26 and Aminopeptidase N/CD13 in Regulation of the Immune Response; In: International Congress Series, 2001, 1218 (Cell-Surface Aminopeptidases: Basic and Clinical Aspects), pages 85-94.	

Examiner Signature	/Christina Bradley/ (11/17/2006)	Date Considered	
-----------------------	----------------------------------	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English Translation is attached.

Burden Hour Statement: The form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to the Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.